莫西沙星治疗耐多药肺结核的临床疗效分析

Clinical efficacy of moxifloxacin in the treatment of multi-drug resistant tuberculosis

目的探讨莫西沙星治疗耐多药肺结核的疗效。方法选择我院收治的耐多药肺结核患者分为两组,在常规治疗的基础上,对照组给予左氧氟沙星,观察组给予莫西沙星。治疗后对临床疗效、痰菌转阴率、病灶吸收有效率、空洞好转率及不良反应进行比较。结果 (1)观察组总有效率明显高于对照组(P<0.05)。(2)观察组各时间段的痰菌转阴率均明显高于对照组(P<0.05)。(3)治疗后两组患者病灶吸收有效率相比,无显著性差异(P>0.05)。(4)治疗后观察组空洞好转率明显高于对照组(P<0.05)。(5)两组患者治疗后不良反应发生率相比,无显著性差异(P>0.05)。结论莫西沙星治疗耐多药肺结核中,明显提高临床疗效,具有一定临床应用价值。

Objective To explore the clinical efficacy of moxifloxacin in the treatment of multi-drug resistant tuberculosis. Methods Multi-drug resistant tuberculosis patients in our hospital were randomly divided into the ob-servation group and the control group. On the basis of conventional treatment, the control group was treated with levo-floxacin, while the observation group was treated with moxifloxacin. The clinical efficacy, the sputum negative con-version rate, lesions absorption, changes in the lung cavity and adverse reactions were compared between the two groups. Results The total efficiency was significantly higher in the observation group than in the control group （P〈0. 05）, and the sputum negative conversion rate was also significantly higher in the observation group than in the con-trol group （P〈0. 05）. There was no significant difference in the lesions absorptive effective rate and adverse reac-tions between the two groups （P〉0. 05）. After the treatment, the improvement rate of lung cavity was significantly better in the observation group than in the control group （ P〈0. 05 ） . Conclusion Moxifloxacin can improve the clinical efficacy in the treatment of multi-drug resistant tuberculosis.